Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

AMX-500 · VIR-5500

Bispecific antibody · Immune activation, directed at prostate-specific membrane antigen (FOLH1) and CD3 (CD3E)

Phase 1 Most advanced trial
1 Registered trials

What is AMX-500?

AMX-500 (also known as VIR-5500) is a protease-activated T-cell engager that binds PSMA on tumor cells and CD3 on T-cells. Its two binding domains are masked by XTEN polypeptides joined through a tumor protease-cleavable linker, so activation occurs in the tumor microenvironment. It is studied in hormone-refractory prostate cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
VIR-5500
Drug type
Bispecific antibody
Targets
prostate-specific membrane antigen (FOLH1), CD3 (CD3E)
Mechanism
Immune activation, directed at prostate-specific membrane antigen (FOLH1) and CD3 (CD3E)
Therapy area
Oncology
In trials of
VIR
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05997615 Phase 1 Hormone-refractory Prostate Cancer Recruiting VIR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hormone-refractory Prostate Cancer

Other drugs acting on FOLH1 / CD3E

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.